Novavax down after Phase III miss for RSV vaccine in infants

Novavax Inc. (NASDAQ:NVAX) lost $1.42 (67%) to $0.71 on Thursday after reporting that its ResVax RSV vaccine missed the primary endpoint in the

Read the full 238 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE